OTCMKTS:SZLSF StageZero Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding StageZero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.06 +0.01 (+18.71%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$0.06▼$0.0650-Day Range$0.06▼$0.0952-Week Range$0.06▼$0.43Volume1,000 shsAverage Volume2,871 shsMarket Capitalization$6.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SZLSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SZLSF Stock Forecast (MarketRank)Overall MarketRank™0.00 out of 5 starsAnalyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for StageZero Life Sciences. Previous Next 0.0 Community Rank Outperform VotesStageZero Life Sciences has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStageZero Life Sciences has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about StageZero Life Sciences and other stocks. Vote “Outperform” if you believe SZLSF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SZLSF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStageZero Life Sciences does not currently pay a dividend.Dividend GrowthStageZero Life Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, StageZero Life Sciences insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of StageZero Life Sciences is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of StageZero Life Sciences is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStageZero Life Sciences has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About StageZero Life Sciences (OTCMKTS:SZLSF)StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.Read More SZLSF Stock News HeadlinesMay 26, 2022 | seekingalpha.comStageZero Life Sciences CFO resignsMay 25, 2022 | finance.yahoo.comStageZero Life Sciences Partners with DiagnoseAtHome to Offer Aristotle(R) Multi-Cancer Blood Test in Canada and USAMay 17, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q1 2022 Financial Results and Operational UpdateMay 17, 2022 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Q1 2022 Financial Results and Operational UpdateApril 6, 2022 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Corporate UpdateApril 1, 2022 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Q4 2021 and Year End Financial Results and Operational UpdateMarch 31, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Launches AVRT in the UKMarch 31, 2022 | finance.yahoo.comStageZero Life Sciences Launches AVRT(TM) in the UKMarch 14, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: CORRECTING AND REPLACING: StageZero Life Sciences Announces Availability of COC Protocol in EuropeMarch 14, 2022 | lse.co.ukCQN:StageZero Announces COC Protocol in EuropeMarch 14, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Announces Availability of COC Protocol in EuropeMarch 14, 2022 | finance.yahoo.comStageZero Life Sciences Announces Availability of COC Protocol in EuropeMarch 3, 2022 | finance.yahoo.comStageZero Life Sciences Announces Closing of CAD$1.87 Million Private Placement with Institutional InvestorSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SZLSF CUSIPN/A CIK1454263 Webwww.stagezerolifesciences.com Phone(855) 420-7140Fax905-209-2031Employees51Year FoundedN/ACompany Calendar Last Earnings3/31/2022Today6/26/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7.48 million Net Margins-20.01% Pretax Margin-19.89% Return on Equity-305.71% Return on Assets-80.91% Debt Debt-to-Equity Ratio0.20 Current Ratio0.29 Quick Ratio0.21 Sales & Book Value Annual Sales$5.07 million Price / Sales1.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book2.12Miscellaneous Outstanding Shares100,730,000Free FloatN/AMarket Cap$6.39 million OptionableNot Optionable Beta0.95 StageZero Life Sciences Frequently Asked Questions How has StageZero Life Sciences' stock price performed in 2022? StageZero Life Sciences' stock was trading at $0.2303 at the beginning of the year. Since then, SZLSF stock has decreased by 72.4% and is now trading at $0.063450. View the best growth stocks for 2022 here. When is StageZero Life Sciences' next earnings date? StageZero Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for StageZero Life Sciences. How were StageZero Life Sciences' earnings last quarter? StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) issued its earnings results on Thursday, March, 31st. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $1.50 million for the quarter. StageZero Life Sciences had a negative net margin of 20.01% and a negative trailing twelve-month return on equity of 305.71%. View StageZero Life Sciences' earnings history. Who are StageZero Life Sciences' key executives? StageZero Life Sciences' management team includes the following people: Mr. James R. Howard-Tripp, Exec. Chairman & CEOProf. Choong-Chin Liew, Co-FounderMr. Warren Whitehead C.M.A., CPA, Chief Accountant (Age 70)Mr. David Suria, Sr. Scientist Who are some of StageZero Life Sciences' key competitors? Some companies that are related to StageZero Life Sciences include Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), Global WholeHealth Partners (GWHP), BG Medicine (BGMD), FluoroPharma Medical (FPMI), Hemagen Diagnostics (HMGN) and Response Genetics (RGDXQ). View all of SZLSF's competitors. What is StageZero Life Sciences' stock symbol? StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "SZLSF." How do I buy shares of StageZero Life Sciences? Shares of SZLSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is StageZero Life Sciences' stock price today? One share of SZLSF stock can currently be purchased for approximately $0.06. How much money does StageZero Life Sciences make? StageZero Life Sciences (OTCMKTS:SZLSF) has a market capitalization of $6.39 million and generates $5.07 million in revenue each year. The company earns $-7.48 million in net income (profit) each year or ($0.03) on an earnings per share basis. How many employees does StageZero Life Sciences have? StageZero Life Sciences employs 51 workers across the globe. How can I contact StageZero Life Sciences? StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The official website for StageZero Life Sciences is www.stagezerolifesciences.com. The company can be reached via phone at (855) 420-7140, via email at [email protected], or via fax at 905-209-2031. This page (OTCMKTS:SZLSF) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
